| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
"Seed-and-Boost" Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy LandscapeImmunoScap...
LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Cue Biopharma (NASDAQ:CUE) with a Buy rating and announces P...
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.14) ...